Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.34 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.34 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.34 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12384652 | 0.78 | KDM4E (0.33) | OPRM1 | |
| SCHEMBL15925075 | 0.78 | KDM4E (0.33) | OPRM1 | |
| SCHEMBL12384802 | 0.78 | KDM4E (0.33) | OPRM1 | |
| SCHEMBL12635251 | 0.77 | DPP4 (0.37) | CHRM2 | |
| SCHEMBL12635252 | 0.77 | DPP4 (0.37) | CHRM2 | |
| SCHEMBL24828000 | 0.77 | KCNH2 (0.30) | KCNH2CACNA1ICACNA1GCHRM2HRH1 | |
| SCHEMBL15925129 | 0.77 | SLC18A3 (0.37) | KCNH2CACNA1ICACNA1GCHRM2HRH1 | |
| SCHEMBL12374972 | 0.76 | HSD11B1 (0.38) | KCNH2OPRL1 | |
| SCHEMBL15925101 | 0.75 | DRD2 (0.38) | — | |
| SCHEMBL23344995 | 0.75 | EPHX2 (0.41) | KCNH2OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426604-B2 | Aminothiazolones as estrogen related receptor-alpha modulators | JANSSEN PHARMACEUTICA NV (BE) | 2013-04-23 | — | — | US | disclosed |
| US-20110200586-A1 | AMINOTHIAZOLONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110200586-A1 | AMINOTHIAZOLONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | ESR2, ESRRA, ESRRG | KCNH2 4494/4885CACNA1I 4592/4885CACNA1G 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.